5/16/2013

A study in JAMA Internal Medicine examined the use of erythropoiesis-stimulating agents after a 2007 FDA black box warning urged facilities to limit their use because of side effects. The study analyzed data involving 275,291 patients.

Full Story:
Reuters

Related Summaries